Akman-Karakaş Ayşe, Yalcin Arzu Didem, Koç Saliha, Gumuslu Saadet, Ergun Erkan, Genc Gizem Esra, Ongut Gozde, Uzun Soner, Alpsoy Erkan
Clin Lab. 2014;60(7):1237-40. doi: 10.7754/clin.lab.2013.130744.
CD200 is a novel immunosuppressive molecule, existing both as cell membrane bound and as a soluble form in serum (sCD200), which acts to regulate inflammatory and acquired immune responses. Recently, our study group showed that sCD200 was found in serum and blister fluid in a patient with bullous pemphigoid and that anti-IgE therapy impacted those levels. We therefore planned this study to evaluate the soluble serum CD200 levels of bullous pemphigoid patients and compare it with that of healthy controls. We also analysed the association between the sCD200 levels and the clinical severity of the disease in bullous pemphigoid patients.
We investigated 5 consecutive patients with bullous pemphigoid, and 15 healthy controls were included in this study. Assessment of clinical examination and measurement of laboratory investigation were performed on the same day. Bullous pemphigoid patients were also assessed for Autoimmune Bullous Skin Disorder Intensity Score (ABSIS). Concentrations of anti-BP180 and soluble CD200 in the serum samples were quantified using ELISA kits.
The serum soluble CD200 level was observed to be statistically significantly higher in patients with BP (77.6 +/- 15.7 pg/mL) compared with healthy controls (26.1 +/- 6.7 pg/mL), (p < 0.001). Nevertheless, there was no statistically significant correlation between serum soluble CD200 levels and clinical severity scores and Anti-BP180 values (p = 0.402, p = 0.395, respectively). However, there was a statistically significant correlation between ABSIS and Anti-BP180 levels in patients with BP (p = 0.036).
CD200 might play a role in the immune response in the pathogenesis of bullous pemphigoid. However, we do not know the exact mechanism of CD200 in the disease initiation and/or progression.
CD200是一种新型免疫抑制分子，以细胞膜结合形式和血清可溶性形式（sCD200）存在，其作用是调节炎症和获得性免疫反应。最近，我们的研究小组发现大疱性类天疱疮患者的血清和疱液中存在sCD200，且抗IgE治疗会影响这些水平。因此，我们计划开展本研究以评估大疱性类天疱疮患者血清可溶性CD200水平，并与健康对照者进行比较。我们还分析了大疱性类天疱疮患者sCD200水平与疾病临床严重程度之间的关联。
我们调查了5例连续性大疱性类天疱疮患者，并纳入15名健康对照者。在同一天进行临床检查评估和实验室检查测量。还对大疱性类天疱疮患者进行了自身免疫性大疱性皮肤病强度评分（ABSIS）评估。使用ELISA试剂盒对血清样本中的抗BP180和可溶性CD200浓度进行定量。
与健康对照者（2,6.1±6.7 pg/mL）相比，BP患者的血清可溶性CD200水平在统计学上显著更高（77.6±15.7 pg/mL），（p<0.001）。然而，血清可溶性CD200水平与临床严重程度评分及抗BP180值之间无统计学显著相关性（分别为p = 0.402，p = 0.395）。但是，BP患者的ABSIS与抗BP180水平之间存在统计学显著相关性（p = 0.036）。
CD200可能在大疱性类天疱疮发病机制的免疫反应中起作用。然而，我们尚不清楚CD200在疾病起始和/或进展中的确切机制。
